Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma

NCT01864109 is registered in ClinicalTrials.gov with Memorial Sloan Kettering Cancer Center as lead sponsor.

NCT NCT01864109
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01864109 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase II Trial of Irinotecan and Temozolomide in Combination With Existing High Dose Alkylator Based Chemotherapy for Treatment of Patients With Newly Diagnosed Ewing Sarcoma
Lead sponsor
Memorial Sloan Kettering Cancer Center
Phase
Phase 2
Overall status
Active, not recruiting
Start date
May 31, 2013
Completion date
May 31, 2027
Enrollment
83 (actual)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

newly diagnosed ewing sarcoma